Adagene Inc. (ADAG)
NASDAQ: ADAG · IEX Real-Time Price · USD
2.710
-0.180 (-6.23%)
Jul 11, 2024, 4:00 PM EDT - Market closed

Company Description

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers.

The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors.

It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs.

The company was incorporated in 2011 and is headquartered in Suzhou, China.

Adagene Inc.
Adagene logo
Country China
Founded 2011
IPO Date Feb 9, 2021
Industry Biotechnology
Sector Healthcare
Employees 174
CEO Dr. Peter P. Luo Ph.D.

Contact Details

Address:
4f, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park
Jiangsu, F4 00000
China
Phone 86-512-87773632
Website adagene.com

Stock Details

Ticker Symbol ADAG
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $19.00
CIK Code 0001818838
CUSIP Number 005329107
ISIN Number US0053291078
SIC Code 2834

Key Executives

Name Position
Dr. Peter P. Luo Ph.D. Co- Founder, Chairman, Chief Executive Officer and President of Research & Development
Man Kin Tam M.B.A. Chief Financial Officer and Director
Dr. Jc Xu M.D., Ph.D. Chief Scientific Officer
Ami Celeste Knoefler Vice President of Investor Relations and Corporate Communications
Ling Zhou Head of Human Resources
Dr. Qinghai Zhao Chief Manufacturing Officer
Yan Li M.B.A. Senior Vice President of Bioinformatics and Information Technology and Director
Xiaohong She Senior Vice President and Head of Clinical Operations
Dr. Guizhong Liu Ph.D. Senior Vice President of Early Drug Discovery
Alexander Goergen Vice President and Head of Business Development

Latest SEC Filings

Date Type Title
Mar 29, 2024 6-K Report of foreign issuer
Mar 29, 2024 424B5 Filing
Mar 29, 2024 20-F Annual and transition report of foreign private issuers
Mar 29, 2024 6-K Report of foreign issuer
Mar 1, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 6-K Report of foreign issuer
Jan 19, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Jan 16, 2024 6-K Report of foreign issuer
Nov 3, 2023 6-K Report of foreign issuer